Imperial College London

Dr. David James PINATO

Faculty of MedicineDepartment of Surgery & Cancer

Clinical Reader in Medical Oncology
 
 
 
//

Contact

 

+44 (0)20 7594 2799david.pinato Website

 
 
//

Location

 

ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Soosaipillai:2021:10.1177/17588359211042224,
author = {Soosaipillai, G and Wu, A and Dettorre, GM and Diamantis, N and Chester, J and Moss, C and Aguilar-Company, J and Bower, M and Sng, C and Salazar, R and Brunet, J and Jones, E and Mesia, R and Jackson, A and Mukherjee, U and Sita-Lumsden, A and Segui, E and Ottaviani, D and Carbo, A and Benafif, S and Wuerstlein, R and Carmona, C and Chopra, N and Cruz, C and Swallow, J and Saoudi, N and Felip, E and Galazi, M and Garcia-Fructuoso, I and Lee, A and Newsom-Davis, T and Wong, S and Sureda, A and Maluquer, C and Ruiz-Camps, I and Cabirta, A and Prat, A and Gennari, A and Ferrante, D and Tabernero, J and Russell, B and Van, Hemelrijck M and Dolly, S and Pinato, D},
doi = {10.1177/17588359211042224},
journal = {Therapeutic Advances in Medical Oncology},
pages = {1--17},
title = {Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective},
url = {http://dx.doi.org/10.1177/17588359211042224},
volume = {13},
year = {2021}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - Background: Specialist palliative care team (SPCT) involvement has been shown to improve symptom control and end-of-life care for patients with cancer, but little is known as to how these have been impacted by the COVID-19 pandemic. Here, we report SPCT involvement during the first wave of the pandemic and compare outcomes for patients with cancer who received and did not receive SPCT input from multiple European cancer centres. Methods: From the OnCovid repository (n=1,318), we analysed cancer patients aged ≥18 diagnosed with COVID-19 between 26th February and 22nd June 2020 who had complete specialist palliative care team (SPCT) data (SPCT+ referred; SPCT- not referred).Results: Of 555 eligible patients, 317 were male (57.1%), with a median age of 70 (IQR 20). At COVID-19 diagnosis, 44.7% were on anti-cancer therapy and 53.3% had >1 co-morbidity. 206 patients received SPCT input for symptom control (80.1%), psychological support (54.4%), and/or advance care planning (51%). SPCT+ patients had more DNACPR orders completed prior to (12.6% vs. 3.7%) and during admission (50% vs 22.1%, P<0.001), with more SPCT+ patients deemed suitable for treatment escalation (50% vs. 22.1%, P<0.001). SPCT involvement was associated with higher discharge rates from hospital for end-of-life care (9.7% vs. 0%, P<0.001). End-of-life anticipatory prescribing was higher in SPCT+ patients, with opioids (96.3% vs. 47.1%) and benzodiazepines (82.9% vs. 41.2%) being used frequently for symptom control.Conclusions: SPCT referral facilitated symptom control, emergency care and discharge planning, as well as high rates of referral for psychological support than previously reported. Our study highlighted the critical need of SPCT for patients with cancer during the pandemic and should inform service planning for this population.
AU - Soosaipillai,G
AU - Wu,A
AU - Dettorre,GM
AU - Diamantis,N
AU - Chester,J
AU - Moss,C
AU - Aguilar-Company,J
AU - Bower,M
AU - Sng,C
AU - Salazar,R
AU - Brunet,J
AU - Jones,E
AU - Mesia,R
AU - Jackson,A
AU - Mukherjee,U
AU - Sita-Lumsden,A
AU - Segui,E
AU - Ottaviani,D
AU - Carbo,A
AU - Benafif,S
AU - Wuerstlein,R
AU - Carmona,C
AU - Chopra,N
AU - Cruz,C
AU - Swallow,J
AU - Saoudi,N
AU - Felip,E
AU - Galazi,M
AU - Garcia-Fructuoso,I
AU - Lee,A
AU - Newsom-Davis,T
AU - Wong,S
AU - Sureda,A
AU - Maluquer,C
AU - Ruiz-Camps,I
AU - Cabirta,A
AU - Prat,A
AU - Gennari,A
AU - Ferrante,D
AU - Tabernero,J
AU - Russell,B
AU - Van,Hemelrijck M
AU - Dolly,S
AU - Pinato,D
DO - 10.1177/17588359211042224
EP - 17
PY - 2021///
SN - 1758-8340
SP - 1
TI - Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective
T2 - Therapeutic Advances in Medical Oncology
UR - http://dx.doi.org/10.1177/17588359211042224
UR - https://journals.sagepub.com/doi/10.1177/17588359211042224
UR - http://hdl.handle.net/10044/1/91111
VL - 13
ER -